PORTLAND, Ore. (AP) – Oregon health officials said Thursday that federal officials are investigating the death of a woman in her 50 with a rare and low platelet count. Within two weeks of receiving the Johnson & Johnson vaccine with COVID-19.
Oregon’s health agency learned of the investigation Tuesday, two days after the U.S. Centers for Disease Control and Prevention began the investigation. The unnamed woman was given the drug before the CDC ordered a temporary stop of vaccination amid concerns that it could cause a dangerous blood clot.
This woman developed a “rare blood clot. But it is fatal with very low platelets, ”the OHA said in a statement.
Dr Shimi Sharief, a senior health advisor at the state health agency, said women̵7;s symptoms were consistent with other cases such as severe headache, abdominal pain, leg pain or shortness of breath.
Public health officials declined to disclose any additional details, including the date the woman was vaccinated or where she lived in Oregon, citing the privacy of the patient. The woman was hospitalized before her death and was vaccinated in early April, Sharief said.
Until the completion of the investigation, which health officials forecast to take a week or more, it was unsure whether her death was related to the vaccine, the agency said.
Federal and state agencies temporarily halted the release of the J&J vaccine on April 13 due to blood clot concerns.
“For most people who get the (J&J) vaccine, we’re close to the end of the time they need to be monitored for symptoms,” Sharief said. The CDC warns that if people develop symptoms within three weeks of getting the vaccine, their provider should be contacted. Take care of their health
Federal officials are examining six reports of unusual blockages, including the deaths of more than 8 million Americans who had received a single vaccination.
The CDC also told Texas health authorities on Thursday that a woman in that state was hospitalized with a blood clot that could be related to a J&J vaccine recipient.
The government advisory committee on the vaccine is expected to meet on Friday and can make recommendations shortly after how and how J&J vaccines will be resumed.
Sharief said Oregon was returning to distribute the J&J vaccine would be a “reflection” of the committee’s decision.
“We are extremely confident that this decision will be thoroughly scrutinized and taken into account the potential benefits and risks associated with it as we go through this epidemic,” Sharief said.
Klein is a member of The Associated Press / Report for America Statehouse News Initiative Report for America, a nonprofit national service program that lets reporters in the local newsroom report undisclosed issues.